Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic naglazyme® (Galsulfase)

AAPS Journal

Volumn 10, Issue 3, 2008, Pages 439-449

  White, Joleen T ^a   Argento Martell, Lisa ^a   Prince, William S ^a   Boyer, Ryan ^a   Crockett, Lucy ^a   Cox, Christopher ^a   Tuyl, Andrea ^a   Aguilera, Allora ^a   Foehr, Erik ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Enzyme replacement therapy; Immunogenicity; MPSVI; Naglazyme; Neutralizing antibody

Indexed keywords

GALSULFASE; NEUTRALIZING ANTIBODY; PHOSPHATE;

ANTIBODY ISOLATION; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME REPLACEMENT; ENZYME SUBSTRATE; HUMAN; IMMUNOASSAY; IN VITRO STUDY; INTERMETHOD COMPARISON; PROCESS DEVELOPMENT; PROTEIN IMMOBILIZATION; SENSITIVITY ANALYSIS;

ANTIBODIES; ANTIBODY FORMATION; BIOTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; N-ACETYLGALACTOSAMINE-4-SULFATASE; PROTEIN BINDING; RECEPTOR, IGF TYPE 2; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 57149092604     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9048-1     Document Type: Article

References (20)

1. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475 (2002).
2. H. P. Hartung, C. Polman, A. Bertolotto, F. Deisenhammer, G. Giovannoni, E. Havrdova, B. Hemmer, J. Hillert, L. Kappos, B. Kieseier, J. Killestein, C. Malcus, M. Comabella, A. Pachner, H. Schellekens, F. Sellebjerg, K. Selmaj, and P. S. Sorensen. Neutralising antibodies to interferon beta in multiple sclerosis: Expert panel report. J. Neurol. 254:827-837 (2007).
3. G. L. Bray, E. D. Gomperts, S. Courter, R. Gruppo, E. M. Gordon, M. Manco-Johnson, A. Shapiro, E. Scheibel, G. White III, and M. Lee. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 83:2428-2435 (1994).
4. P. S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, W. L. Hwu, N. Leslie, J. Levine, C. Spencer, M. McDonald, J. Li, J. Dumontier, M. Halberthal, Y. H. Chien, R. Hopkin, S. Vijayaraghavan, D. Gruskin, D. Bartholomew, P. A. van der, J. P. Clancy, R. Parini, G. Morin, M. Beck, G. S. De la Gastine, M. Jokic, B. Thurberg, S. Richards, D. Bali, M. Davison, M. A. Worden, Y. T. Chen, and J. E. Wraith. Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology. 68:99-109 (2007).
5. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360 (2002).
6. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S. J. Swanson, G. Taniguchi, D. Wierda, and L. A. Zuckerman. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods. 289:1-16 (2004).
7. S. Gupta, S. R. Indelicato, V. Jethwa, T. Kawabata, M. Kelley, A. R. Mire-Sluis, S. M. Richards, B. Rup, E. Shores, S. J. Swanson, and E. Wakshull. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods. 321:1-18 (2007).
8. E. F. Neufield, and J. Muenzer. The mucopolysaccharidoses. In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (eds.), The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Medical, New York, 2001, pp. 3421-3452.
9. B. Winchester, A. Vellodi, and E. Young. The molecular basis of lysosomal storage diseases and their treatment. Biochem. Soc. Trans. 28:150-154 (2000).
10. W. L. Nyhan, and P. T. Ozand. Atlas of Metabolic Diseases, Chapman and Hall Medical, London; New York, 1998.
11. P. Harmatz, C. B. Whitley, L. Waber, R. Pais, R. Steiner, B. Plecko, P. Kaplan, J. Simon, E. Butensky, and J. J. Hopwood. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 144:574-580 (2004).
12. P. Harmatz, D. Ketteridge, R. Giugliani, N. Guffon, E. L. Teles, M. C. Miranda, Z. F. Yu, S. J. Swiedler, and J. J. Hopwood. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N -acetylgalactosamine 4-sulfatase. Pediatrics. 115:e681-e689 (2005).
13. P. Harmatz, W. G. Kramer, J. J. Hopwood, J. Simon, E. Butensky, and S. J. Swiedler. Pharmacokinetic profile of recombinant human N -acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): A phase I/II study. Acta Paediatr. Suppl. 94:61-68 (2005).
14. P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E. L. Teles, M. C. Miranda, J. E. Wraith, M. Beck, L. Arash, M. Scarpa, Z. F. Yu, J. Wittes, K. I. Berger, M. S. Newman, A. M. Lowe, E. Kakkis, and S. J. Swiedler. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N -acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 148:533-539 (2006).
15. S. M. Dintzis, V. E. Velculescu, and S. R. Pfeffer. Receptor extracellular domains may contain trafficking information. Studies of the 300-kDa mannose 6-phosphate receptor. J. Biol. Chem. 269:12159-12166 (1994).
16. A. C. Crawley, D. A. Brooks, V. J. Muller, B. A. Petersen, E. L. Isaac, J. Bielicki, B. M. King, C. D. Boulter, A. J. Moore, N. L. Fazzalari, D. S. Anson, S. Byers, and J. J. Hopwood. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 97:1864-1873 (1996).
17. D. E. Sleat, Y. Wang, I. Sohar, H. Lackland, Y. Li, H. Li, H. Zheng, and P. Lobel. Identification and validation of mannose 6-phosphate glycoproteins in human plasma reveal a wide range of lysosomal and non-lysosomal proteins. Mol. Cell. Proteomics. 5:1942-1956 (2006).
18. C. S. Hanes. Studies on plant amylases: The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. Biochem. J. 26:1406-1421 (1932).
19. J. T. White, L. A. Martell, A. Van Tuyl, R. Boyer, L. Warness, G. Taniguchi, and E. Foehr. development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase), AAPS J. (2008). doi: 10.1208/s12248-008-9043-6.
20. EMEA Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins, EMEA/CHMP/BMWP/14327/2006. April 2008.